CEO Clips - Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial

Stock Information for Algernon Pharmaceuticals

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Algernon Pharmaceuticals

Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000
Algernon Announces $1M Private Placement
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
Algernon Announces Warrant Extension
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.